Provention warns FDA requests could delay diabetes approval

Provention Bio has warned the approval of teplizumab in Type 1 diabetes is likely to be delayed by a request for more information from the FDA. The advisory committee meeting is still scheduled to go ahead late next month, but the July 2 PDUFA date is now under threat.